Morphle Labs, a Bengaluru-based deep-tech startup, has secured US $5 million in a Series A round led by Inflexor Ventures to scale its robotic and imaging platforms aiming to automate core steps in cancer-diagnostics histopathology and reduce reliance on manual lab work
Glimpse:
The funding will boost manufacturing of its flagship products RoboTome (robotic microtome) and MorphoLens (high-throughput digital slide scanner), support global regulatory approvals, and expand its global market presence. By automating tissue slicing and slide imaging, Morphle seeks to cut diagnostic times, improve consistency, and address global pathology workforce shortages.
Morphle Labs, founded in 2017 and headquartered in Bengaluru (with operations also in Boston), has raised a USD 5 million Series A round led by Inflexor Ventures to accelerate its mission of transforming histopathology, the backbone of cancer diagnostics worldwide.
The company’s core innovation lies in two devices: RoboTome, the first-of-its-kind robotic microtome that slices biopsy blocks at over twice the speed of experienced histotechnologists while maintaining sectioning quality; and MorphoLens, a high-throughput digital slide scanner capable of digitising more than 100 slides per hour using advanced optics and AI-driven imaging. Together, these systems automate some of the most labor-intensive, error-prone steps in histology a critical bottleneck in timely and accurate cancer diagnosis. ew funding, Morphle plans to scale up manufacturing of RoboTome and MorphoLens, expand its engineering and research teams, and pursue regulatory approvals required for global market entry. The company aims to combine robotics, precision hardware, optics, and AI to build what it calls “physical AI” where intelligent software and high-performance hardware deliver reliable, high-throughput diagnostic workflows.
According to founder & CEO Rohit Hiwale, histology remains one of healthcare’s most underserved domains for automation. “With RoboTome and MorphoLens, we have tackled two of the most challenging bottlenecks in diagnostics but this is only the beginning,” he said, adding that the broader goal is to create a seamless, end-to-end pathology workflow from tissue sample to digital interpretation that reduces turnaround time and improves diagnostic quality globally.
“Histology remains one of the few critical domains still untouched by true automation with RoboTome and MorphoLens, we’re building a future where labs deliver faster, higher-quality cancer diagnoses and pathologists can focus on the diagnosis, not the drudgery.”
By
HB Team
